全文获取类型
收费全文 | 199篇 |
免费 | 5篇 |
国内免费 | 3篇 |
专业分类
儿科学 | 4篇 |
妇产科学 | 1篇 |
基础医学 | 13篇 |
口腔科学 | 2篇 |
临床医学 | 17篇 |
内科学 | 84篇 |
皮肤病学 | 3篇 |
神经病学 | 5篇 |
特种医学 | 4篇 |
外科学 | 24篇 |
综合类 | 2篇 |
预防医学 | 5篇 |
眼科学 | 4篇 |
药学 | 30篇 |
肿瘤学 | 9篇 |
出版年
2023年 | 2篇 |
2022年 | 2篇 |
2021年 | 11篇 |
2020年 | 6篇 |
2019年 | 5篇 |
2018年 | 6篇 |
2017年 | 5篇 |
2016年 | 2篇 |
2015年 | 8篇 |
2014年 | 9篇 |
2013年 | 8篇 |
2012年 | 14篇 |
2011年 | 15篇 |
2010年 | 7篇 |
2009年 | 6篇 |
2008年 | 8篇 |
2007年 | 18篇 |
2006年 | 10篇 |
2005年 | 6篇 |
2004年 | 16篇 |
2003年 | 9篇 |
2002年 | 5篇 |
2001年 | 5篇 |
2000年 | 5篇 |
1999年 | 2篇 |
1998年 | 6篇 |
1997年 | 1篇 |
1995年 | 1篇 |
1994年 | 1篇 |
1989年 | 1篇 |
1988年 | 3篇 |
1986年 | 1篇 |
1982年 | 1篇 |
1975年 | 1篇 |
1971年 | 1篇 |
排序方式: 共有207条查询结果,搜索用时 15 毫秒
1.
Noninvasive metabolic magnetic resonance (MR) imaging reflecting glucose metabolism in the aldose-reductase-sorbitol (ARS) pathway was performed in the rabbit head; after administration of the fluorinated glucose analogue 3-fluoro-3-deoxy-D-glucose (3FD-glucose), fluorine-19 images were generated. Images of 3FD-glucose showed significant 3FD-glucose uptake by adipose tissue, indicating its buffering effects in case of excess loads of glucose. Images of 3-fluoro-3-deoxy-D-sorbitol (3FD-sorbitol) demonstrated the spatial distribution of aldose reductase activities and significant sorbitol accumulation in the lens. Images of 3-fluoro-3-deoxy-D-fructose (3FD-fructose) showed preferential uptake of fructose by muscle tissue. The extremely low toxicity of 3FD-glucose indicates promise for its clinical application in metabolic imaging. 相似文献
2.
Sarah Suh Emily Hetzel Katie Alter-Troilo Kathleen Lak Jon C. Gould Tammy L. Kindel Rana M. Higgins 《Surgery for obesity and related diseases》2021,17(8):1480-1488
BackgroundPreoperative carbohydrate loading is a component of Enhanced Recovery After Surgery (ERAS) protocols, but there is limited literature in bariatric surgery patients.ObjectivesThe objective of this study was to characterize the impact of preoperative carbohydrate loading on postoperative bariatric surgery outcomes.SettingUniversity Hospital.MethodsPatients undergoing a primary minimally invasive Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) between 2018 and 2020 were randomized to standard management or intervention. Standard management patients were nothing by mouth (NPO) after midnight prior to surgery. Intervention patients consumed 2 carbohydrate drinks: 1 the night before and another 3 hours prior to surgery. Primary outcomes analyzed included postoperative nausea and vomiting (PONV), length of stay, and overall complications.ResultsIn total, 134 patients were analyzed: 64 intervention (47.8%) and 70 (52.2%) standard. In the end, 7% and 15% of patients were lost to follow-up at 6-weeks and 3-months, respectively. There was no statistically significant difference in length of stay (2.0 ± 1.2 vs 2.1 ± .9 d; P = .65) or postoperative outcomes between the 2 groups. There were no episodes of aspiration among the intervention group. Among RYGB patients, intervention patients had a shorter duration of nausea compared with standard patients. There was no significant difference in glycemic control among patients with and without diabetes.ConclusionsPreoperative carbohydrate drinks can be administered to bariatric surgery patients without significant risks. Carbohydrate loading preoperatively can decrease the duration of PONV in RYGB patients. Carbohydrate drinks can be safely included in bariatric ERAS protocols for patients with and without diabetes, although the benefits remain unknown. 相似文献
3.
Vutisiri Veerasarn Chonlakiet Khorprasert Vicharn Lorvidhaya Supatra Sangruchi Thanatip Tantivatana Ladawan Narkwong Yongyut Kongthanarat Imjai Chitapanarux Chanawat Tesavibul Apichart Panichevaluk Sirisak Puribhat Somphob Sangkittipaiboon Lak Sookpreedee Prasert Lertsanguansinchai Pramook Phromratanapongse Poonkiat Rungpoka Supamitr Trithratipvikul Bannakij Lojanapiwat Sathit Ruangdilokrat Pichai Ngampanprasert 《Radiotherapy and oncology》2004,73(2):179-185
BACKGROUND AND PURPOSE: To evaluate the efficacy and the safety of WF10 as adjunct to standard treatment in the management of late hemorrhagic radiation cystitis compared to standard treatment alone. PATIENTS AND METHODS: Cervical cancer patients with Grade 2 or 3 late hemorrhagic radiation cystitis, were randomized and treated with WF10 0.5 ml/kg body weight, diluted in physiological saline or 5% dextrose water 250 ml, intravenous infusions over 2 h on 5 consecutive days, every 3 weeks for 2 cycles plus standard treatment (WF10 group) or standard treatment alone (control group). Fifty patients in each group were evaluated by questioning; urinalysis and cystoscopy during a 1 year follow up. RESULTS: At week 7, 37 patients (74%) in the WF10 group and 32 patients (64%) in the control group showed complete resolution in objective hematuria (P = 0.28). Significantly lower use of antibiotics (P = 0.002) and antispasmodics (P < 0.001) was found in the WF10 group. Among the responders, 24 patients (77%) in the control group experienced recurrent objective hematuria, whereas in the WF10 group only 17 patients (47%) experienced a recurrence (P = 0.01). Recurrence of objective hematuria occurred significantly faster in the control group as evidenced by Kaplan-Meier and log-rank statistics (P = 0.004), suggesting a long-term effect of WF10. Cystoscopy, at the end of the treatment period and after the one year follow up showed overall improvement without significant difference between two groups. No severe toxicity was monitored. CONCLUSIONS: WF10 therapy is a safe, non-invasive and convenient method in the management of late hemorrhagic radiation cystitis. WF10 therapy, as adjunct to standard treatment, has significantly reduced recurrence of objective hematuria, compared to standard treatment alone, during a one year follow up. 相似文献
4.
Yoon Jin Choi Yong Chan Lee Jung Mogg Kim Jin Il Kim Jeong Seop Moon Yun Jeong Lim Gwang Ho Baik Byoung Kwan Son Hang Lak Lee Kyoung Oh Kim Nayoung Kim Kwang Hyun Ko Hye-Kyung Jung Ki-Nam Shim Hoon Jai Chun Byung-Wook Kim Hyuk Lee Jie-Hyun Kim Hyunsoo Chung Sang Gyun Kim Jae Young Jang 《Gut and liver》2022,16(4):535
Background/AimsWe examined the efficacy and safety of tegoprazan as a part of first-line triple therapy for Helicobacter pylori eradication.MethodsA randomized, double-blind, controlled, multicenter study was performed to evaluate whether tegoprazan (50 mg)-based triple therapy (TPZ) was noninferior to lansoprazole (30 mg)-based triple therapy (LPZ) (with amoxicillin 1 g and clarithromycin 500 mg; all administered twice daily for 7 days) for treating H. pylori. The primary endpoint was the H. pylori eradication rate. Subgroup analyses were performed according to the cytochrome P450 (CYP) 2C19 genotype, the minimum inhibitory concentration (MIC) of amoxicillin and clarithromycin, and underlying gastric diseases.ResultsIn total, 350 H. pylori-positive patients were randomly allocated to the TPZ or LPZ group. The H. pylori eradication rates in the TPZ and LPZ groups were 62.86% (110/175) and 60.57% (106/175) in an intention-to-treat analysis and 69.33% (104/150) and 67.33% (101/150) in a per-protocol analysis (non-inferiority test, p=0.009 and p=0.013), respectively. Subgroup analyses according to MICs or CYP2C19 did not show remarkable differences in eradication rate. Both first-line triple therapies were well-tolerated with no notable differences.ConclusionsTPZ is as effective as proton pump inhibitor-based triple therapy and is as safe as first-line H. pylori eradication therapy but does not overcome the clarithromycin resistance of H. pylori in Korea (ClinicalTrials.gov identifier ). NCT03317223相似文献
5.
Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran 总被引:3,自引:0,他引:3
Toogeh G Sharifian R Lak M Safaee R Artoni A Peyvandi F 《American journal of hematology》2004,77(2):198-199
Glanzmann thrombasthenia (GT) is a rare autosomal recessive disease characterized by prolonged bleeding time with normal platelet count and morphology. It is caused by the quantitative or qualitative deficiency of the platelet glycoprotein IIb-IIIa. In 382 Iranian patients with GT diagnosed at a single center during the period 1969-2001, consanguinity between parents was 86.6%, in accord with the high frequency of intrafamilial marriages in Iran. Almost all patients had had abnormal mucocutaneous bleeding (epistaxis and gum bleeding); at follow-up, 4/5 of the patients had been transfused at least once to control hemorrhagic episodes. As expected, almost all the patients had a normal platelet count while the leukocyte count was increased in 19.3%. Among women, an unexpected low rate of pregnancies was observed. 相似文献
6.
Hang Lak Lee Joo Hyun Sohn Jin Bae Kim Dong Soo Han Yong Chul Jeon Joon Soo Hahm Dong Hoo Lee Chun Suk Kee Yong Wook Park 《Taehan Sohwagi Hakhoe chi》2005,46(3):233-236
Leiomyosarcoma is an uncommon tumor which arises from various sites including uterus, stomach, retroperitoneum, superficial soft tissues, bladder, kidney, and lung. Primary hepatic leiomyosarcoma is a very rare tumor and fewer than 70 cases of primary hepatic leiomyosarcoma have been reported since the first publication in Japan. And there was only one case report of cutaneous metastasis from hepatic leiomyosarcoma. We recently experienced a case of primary hepatic leiomyosarcoma presenting as subcutaneous palpable mass. Herein we report this case with a review of literatures. 相似文献
7.
8.
9.
Hyo‐Lim Hong Sung‐Han Kim Dong Lak Choi Hyun Hee Kwon 《American journal of transplantation》2020,20(10):2938-2941
Coronavirus disease 2019 (COVID‐19) is a novel infectious disease that continues to spread on a global scale. There has been growing concern about donor‐derived transmissions of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Herein, we present the case of a patient who underwent ABO‐incompatible living donor liver transplantation without knowing that the liver donor was infected with COVID‐19 during the donation procedure. In this case, the donor‐derived transmission to the recipient was not identified, and the liver donor was found to be recovering from a COVID‐19 infection. The donor‐derived transmission was not identified. 相似文献
10.